Kymera hands the helm to Novartis vet — and founding CSO — Nello Mainolfi

John Carroll

Editor & Founder

Kymera Therapeutics is turning to a co-founder to run the company.
The protein degradation specialist with a deep-pocket syndicate behind them has opted …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Kymera hands the helm to Novartis vet — and founding CSO — Nello Mainolfi

John Carroll

Editor & Founder

Sign up to read this article for free.

A look at biotech's year of the megaround

After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play

Regeneron buys London-based ocular biotech

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Neumora's major depression drug flunks first of three Phase 3 trials

Novo petitions FDA over Victoza compounding as first generic wins approval

Kymera hands the helm to No­var­tis vet — and found­ing CSO — Nel­lo Main­olfi

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

A look at biotech's year of the megaround

Af­ter Ca­griSe­ma, eyes are on Lil­ly’s oral GLP-1 as next key obe­si­ty play

Re­gen­eron buys Lon­don-based oc­u­lar biotech

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

No­vo pe­ti­tions FDA over Vic­toza com­pound­ing as first gener­ic wins ap­proval

Kymera hands the helm to Novartis vet — and founding CSO — Nello Mainolfi

After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play

Regeneron buys London-based ocular biotech

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Neumora's major depression drug flunks first of three Phase 3 trials

Novo petitions FDA over Victoza compounding as first generic wins approval